Researcher
Rosanne Janssens
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Sep 2016 → Today
Projects
1 - 5 of 5
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Optimizing the conduct and implementation of patient preference research in drug development and evaluation: a focus on oncology and COVID-19From22 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Patient preferences in cardiology: methodological aspects and integration decision-makingFrom6 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Integrating shared decision making in Belgian clinical practiceFrom10 Sep 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Patient Preferences in Drug Development and Evaluation: Issues and RecommendationsFrom3 Oct 2016 → 20 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 26
- Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences(2024)
Authors: Rosanne Janssens
Pages: 203 - 216 - How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action(2023)
Authors: Rosanne Janssens, Liese Barbier, Elise Schoefs, Isabelle Huys
- Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives(2023)
Authors: Rosanne Janssens, Elise Schoefs, Kristiaan Nackaerts, Isabelle Huys
- Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group(2023)
Authors: Rosanne Janssens, Isabelle Huys, Liese Barbier
- Patients as research partners in preference studies: learnings from IMI-PREFER.(2023)
Authors: Rosanne Janssens, Isabelle Huys
Pages: 21 - What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study(2023)
Authors: Elise Schoefs, Séverine Vermeire, Marc Ferrante, João Guedelha Sabino, Rosanne Janssens, Isabelle Huys
Pages: 379 - 388 - What matters most to patients with multiple myeloma? A Pan-European patient preference study(2022)
Authors: Rosanne Janssens, Elise Schoefs, Michel Delforge, Martina Vandebroek, Steven Simoens, Isabelle Huys
- How to balance valuable innovation with affordable access to medicines in Belgium?(2022)
Authors: Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Evelien De Sutter, Rosanne Janssens, Teodora Lalova-Spinks, Robbe Saesen, et al.
- Patient Preferences in Drug Development and Evaluation: Issues and Recommendations(2021)
Authors: Rosanne Janssens, Isabelle Huys, Steven Simoens, Hilde Stevens
- Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy(2021)
Authors: Rosanne Janssens, Elise Schoefs, Kristiaan Nackaerts, Isabelle Huys